<DOC>
	<DOCNO>NCT02640053</DOCNO>
	<brief_summary>This randomize pilot clinical trial study topical cryotherapy ( procedure extremely cold liquid use freeze destroy abnormal tissue ) reduce pain patient chemotherapy induced peripheral neuropathy paclitaxel induce acute pain syndrome . Peripheral neuropathy nerve problem cause pain , numbness , tingle , swell , muscle weakness different part body . Paclitaxel produce disable syndrome acute ache pain . Topical cryotherapy may help relieve pain peripheral neuropathy acute pain syndrome cause chemotherapy .</brief_summary>
	<brief_title>Topical Cryotherapy Reducing Pain Patients With Chemotherapy Induced Peripheral Neuropathy Paclitaxel Induced Acute Pain Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate whether topical cryotherapy alleviate paclitaxel-induced peripheral neuropathy . II . To estimate whether topical cryotherapy alleviate paclitaxel-induced acute pain syndrome ( P-APS ) . III . To examine possible relative toxicity relate topical cryotherapy study situation . OUTLINE : Patients randomize 1 2 arm . ARM I : Patients apply bag fill crushed ice hand foot 15 minute , 60 minute administration , 15 minute finish administration paclitaxel . ARM II : Patients receive paclitaxel intravenously ( IV ) 60 minute week 1-12 . In arm , course repeat week 12 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 30 day 6 month .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Acute Pain</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Ability complete questionnaire assistance Planned paclitaxel dose 80 mg/m^2 intravenously ( I.V . ) give , adjuvant breast cancer ( postoperative neoadjuvant ) setting , every week plan course 12 week without concurrent cytotoxic chemotherapy ( NOTE : trastuzumab and/or antibody and/or small molecule treatment allow , except poly adenosine diphosphate ribose polymerase [ PARP ] inhibitor ) , enter Academic Community Cancer Research United ( ACCRU ) institution Life expectancy &gt; 6 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient score 0 1 neurotoxicity evaluation , determine healthcare provider Previous diagnosis diabetic neuropathy peripheral neuropathy cause Diagnosis fibromyalgia Any prior exposure neurotoxic chemotherapy History Raynaud 's disease , cryoglobulinemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>